Answers are grounded in this paper and cite their sources.
Treatment with RGRN-305 showed acceptable safety, especially in the low-dose group, and was associated with clinically meaningful improvement in a subset of patients with plaque psoriasis, indicating that HSP90 may serve as a novel future target in psoriasis treatment.
No takes yet. Share an insight, caveat, or question.
Bregnhøj et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: